Efficacy and safety of tenofovir and entecavir in patients with chronic hepatitis B-related cirrhosis: a systematic review and meta-analysis

Efficacy and safety of tenofovir and entecavir in patients with chronic hepatitis B-related cirrhosis: a systematic review and meta-analysis

ObjectivesTo systematically evaluate the efficacy and safety of tenofovir and entecavir in chronic hepatitis B-related cirrhosis.MethodsA comprehensive search was conducted in databases including PubMed, Web of Science, Embase and Cochrane Library from the inception until June 2024. Studies on the u...

Full description

Saved in:

Bibliographic Details
Main Authors:	Lu Cao, Li Li, Lixing Yang, Nan Zhou, Yu Zhang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-01-01
Series:	Frontiers in Pharmacology
Subjects:	meta-analysis tenofovir entecavir chronic hepatitis B cirrhosis
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1507117/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Experience of entecavir in renal graft recipients with chronic hepatitis B
by: M. L. Zubkin, et al.
Published: (2011-09-01)

Long-Term Real-World Outcomes of Tenofovir Alafenamide in Chronic Hepatitis B: Detailed Analysis of Treatment-Naive and Experienced Patients
by: Yu-Xuan Song, et al.
Published: (2025-01-01)

Efficacy of nucleoside analogues for hepatitis B virus-related liver failure: A network meta-analysis
by: Wu Jian, et al.
Published: (2018-03-01)

Chronic glomerulonephritis of the mixed type in patient with HBV-infection (<i>Clinical case</i>)
by: V. S. Adonyeva, et al.
Published: (2013-07-01)

Virological and serological outcomes in people with HIV-HBV coinfection who had discontinued tenofovir-containing antiretroviral therapy: Results from a prospective cohort study
by: Amir M. Mohareb, et al.
Published: (2024-12-01)

Decrease in HBsAg After TAF Switching from Entecavir During Long-Term Treatment of Chronic Hepatitis B Virus Infection
by: Kazuto Tajiri, et al.
Published: (2024-12-01)

Effect of potent nucleos(t)ide analog on alpha fetoprotein changes and occurrence of hepatocellular carcinoma in patients with chronic hepatitis B
by: Qianqian Ma, et al.
Published: (2025-02-01)

Entecavir: stability and drug-excipient compatibility
by: Ariadne Botto Fiorot, et al.
Published: (2025-01-01)

Risk of Cirrhosis in Patients with Non-alcoholic Fatty Liver Disease and Previous Viral Hepatitis B
by: S. N. Batskikh, et al.
Published: (2020-09-01)

Long-Term Results of the Etiotropic Therapy of Subcompensed Liver Cirrhosis in the Outcome of Chronic Hepatitis C
by: P. O. Bogomolov, et al.
Published: (2020-01-01)

Identification of multiple complications as independent risk factors associated with 1-, 3-, and 5-year mortality in hepatitis B-associated cirrhosis patients
by: Duo Shen, et al.
Published: (2025-02-01)

A new prognostic model based on serum apolipoprotein AI in patients with HBV-ACLF and acutely decompensated liver cirrhosis
by: Ruidong Mo, et al.
Published: (2025-02-01)

Infection with hepatitis C virus as a cause of cirrhosis – case study
by: Lidia Sierpińska, et al.
Published: (2025-01-01)

A Cytokine That Is Involved in Immune Responses in Chronic Hepatitis B Virus Patients
by: Noor R. Abady, et al.
Published: (2024-01-01)

Risk of progression and the cause of mortality at chronic viral mixed-hepatitis
by: K. I. Yesmembetov, et al.
Published: (2013-07-01)

Efficacy and safety of new protease inhibitor faldaprevir in treatment of hepatitis C
by: M. V. Mayevskaya, et al.
Published: (2013-12-01)

The role of multifocal visual evoked potential in detection of minimal hepatic encephalopathy in patients with compensated liver cirrhosis
by: Reem M. Sabry, et al.
Published: (2025-02-01)

Diastolic dysfunction of myocardium and change of <i>Q–T</i> interval at chronic hepatitis C
by: A. A. Konysheva, et al.
Published: (2012-11-01)

Hepatic encephalopathy and spontaneous bacterial peritonitis are associated with increased liver-related readmissions in cirrhosis
by: Shan Wang, et al.
Published: (2025-01-01)

Resolved Hepatitis B: Achieved or Imaginary Wellbeing?
by: S. N. Batskikh
Published: (2021-04-01)

Impact of hepatic steatosis on the efficacy of antiviral treatment for chronic hepatitis B and the establishment of predictive model: a cohort study
by: Guanghui Ren, et al.
Published: (2025-02-01)

Associations between changes in the gut microbiota and liver cirrhosis: a systematic review and meta-analysis
by: Ye Liu, et al.
Published: (2025-01-01)

Lower incidence of hepatocellular carcinoma with tenofovir alafenamide in chronic hepatitis B: Evidence from a large-scale cohort
by: Hye-Jin Yoo, et al.
Published: (2025-02-01)

Markers of chronic hepatitis B at patients with HIV-infection and treatment approaches
by: S. I. Maksimov, et al.
Published: (2010-11-01)

Efficacy and safety of the first domestic pegilated interferon alpha-2b «Pegaltevir» at chronic hepatitis C: pilot data of phase III clinical study
by: V. T. Ivashkin, et al.
Published: (2014-07-01)

Kidney disease among adults on tenofovir-based second-line antiretroviral therapy in Dar es Salaam, Tanzania
by: Sabina F. Mugusi, et al.
Published: (2025-01-01)

Wilson’s Disease and Autoimmune Hepatitis Coexistence: A Cause of Diagnostic Delay
by: Mohammed G Mudawi, et al.
Published: (2023-09-01)

Issues occult hepatitis B virus infection
by: I. A. Morozov, et al.
Published: (2012-07-01)

Association of hepatitis B virus DNA levels with efficacy and safety and the impact of antiviral therapy on prognosis in liver cancer patients receiving immune checkpoint inhibitors therapy: a systematic review and meta-analysis
by: Hongxia Cui, et al.
Published: (2025-01-01)

Efficacy of pegylated interferon alfa-2b «Algeron» in the treatment of chronic hepatitis C
by: M. V. Mayevskaya, et al.
Published: (2013-03-01)

Effectiveness of glecaprevir/pibrentasvir in HIV/HCV-coinfected patients treated with bictegravir/emtricitabine/tenofovir alafenamide
by: Aleksandra Berkan-Kawińska, et al.
Published: (2024-07-01)

Assessment of serum Mac-2 binding protein glycosylation isomer as a potential marker for hepatocellular carcinoma in cirrhotic hepatitis C patients
by: Mohamed Gamal, et al.
Published: (2024-06-01)

Lifetime of patients and prognostic value of manifestations and complications of liver cirrhosis
by: G. K. Mirodzhov, et al.
Published: (2010-11-01)

DIABETES MELLITUS IN PATIENTS WITH LIVER CIRRHOSIS: NEW TREATMENT OPTIONS
by: L. Yu. Morgunov
Published: (2017-09-01)

Role of alpha-fetoprotein in complex diagnostics of progressing course of chronic hepatitis B and C
by: I. A. Belavina, et al.
Published: (2012-06-01)

Inflammatory lipid biomarkers and transplant-free mortality risk in hepatitis B-related cirrhosis and hepatic encephalopathy
by: Ke Shi, et al.
Published: (2025-01-01)

Antiviral therapy and regression of liver fibrosis at chronic hepatitis B
by: D. T. Abdurakhmanov
Published: (2010-02-01)

Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases—meta‐analytic assessment
by: Kazuo Tarao, et al.
Published: (2019-03-01)

Diagnosis and presenting features of autoimmune hepatitis at a central referral hospital in South Africa
by: Y Maharaj, et al.
Published: (2024-04-01)

Triple antiviral therapy in patient with liver cirrhosis: complications and options of pharmacological treatment
by: M. V. Mayevskaya, et al.
Published: (2014-08-01)